Bisoprolol

Why this drug is interesting

Bisoprolol is among the most commonly prescribed cardiac drugs in the UK, and one an emergency physician will almost never initiate. There is no intravenous preparation, and its 10–12 hour half-life means it is a maintenance drug, not an acute one. For the tachycardic patient in resus, the intravenous beta-blocker is metoprolol.

What emergency clinicians do face, repeatedly, is a decision about someone else's bisoprolol: the patient in decompensated heart failure who takes it, the bradycardic patient in whom it may be culpable, the septic patient whose blunted heart rate response is masking severity, the overdose. Those decisions are where the useful knowledge lies.

Pharmacology

Mechanism

Bisoprolol is a competitive antagonist at beta-1 adrenoceptors with the highest beta-1 selectivity of the beta-blockers in routine UK use. It has no intrinsic sympathomimetic activity and no significant membrane-stabilising effect.

In chronic heart failure, the benefit is not haemodynamic in the short term — beta-blockade initially reduces cardiac output. The gain comes from attenuating chronic sympathetic overactivity: reduced myocardial oxygen demand, reduced arrhythmia burden, and reverse remodelling over months. This is why the titration is slow and why the drug feels wrong before it feels right.

Kinetics

Bioavailability

About 90% — high and predictable, with little first-pass metabolism

Half-life

10–12 hours in healthy subjects — but 17±5 hours in heart failure patients, i.e. in the population most of this page concerns. Once-daily dosing holds in both

Elimination

Balanced — roughly 50% hepatic metabolism, 50% renal excretion unchanged

Lipophilicity

Relatively hydrophilic — less CNS penetration, so fewer nightmares than metoprolol

Indications and dosing

Licensed indications

• Stable chronic heart failure with reduced left ventricular systolic function, in addition to ACE inhibitors, diuretics and optionally cardiac glycosides¹
• Hypertension
• Chronic stable angina

Rate control in atrial fibrillation is extremely common practice and is supported by NICE, which recommends a standard beta-blocker (other than sotalol) as a first-line rate-control option — but check the SmPC for the specific product, as AF rate control is not on every bisoprolol licence.

Heart failure titration

The SmPC schedule is deliberately slow, and the patient must be stable, without acute failure, when treatment is initiated. The SmPC also recommends that the initiating physician be experienced in managing chronic heart failure.¹

Other dosing

For hypertension, angina and rate control, typical doses are 2.5–10 mg once daily, titrated to effect and tolerance. Reduce in severe renal or hepatic impairment.

The decision emergency clinicians actually face

Bisoprolol is far more often a variable in someone's presentation than a treatment you prescribe. Four recurring situations:

1. Acute decompensated heart failure in a patient established on it

2. Bradycardia

A rate in the 40s in a patient on bisoprolol is frequently the drug — but not always, and the reflex to blame it can bury complete heart block, hyperkalaemia, hypothyroidism, an inferior infarct or another rate-limiting drug. Look for all of those before attributing.

3. The blunted physiological response

4. Overdose

Beta-blocker poisoning presents with bradycardia, hypotension, and — in contrast to calcium channel blocker overdose — a tendency to hypoglycaemia rather than hyperglycaemia. Management involves atropine, glucagon, high-dose insulin, vasopressors and early critical care and toxicology input. Consult TOXBASE. See Verapamil for the calcium channel blocker comparison.

Contraindications and adverse effects

Contraindications

• Acute heart failure, or decompensation requiring intravenous inotropic therapy
• Cardiogenic shock
• Second- or third-degree AV block without a pacemaker
• Sick sinus syndrome, sino-atrial block
• Symptomatic bradycardia or symptomatic hypotension
• Severe bronchial asthma or severe chronic obstructive pulmonary disease
• Severe peripheral arterial occlusive disease or Raynaud's
• Untreated phaeochromocytoma
• Metabolic acidosis

Adverse effects

• Fatigue — the commonest reason for discontinuation, and often improving after the first weeks
• Bradycardia, hypotension, worsening heart failure during titration
• Cold extremities, claudication
• Dizziness, headache
• Bronchospasm — dose-related
• Masking of hypoglycaemic warning symptoms in diabetes
• Sleep disturbance and nightmares — less than with lipophilic agents such as metoprolol
• Sexual dysfunction

Critical appraisal

1. The heart failure evidence is genuinely strong. CIBIS-II demonstrated a clear mortality reduction with bisoprolol in chronic heart failure with reduced ejection fraction, and beta-blockade remains one of the four pillars of HFrEF therapy. This is not an area of controversy.
2. That evidence does not extend to heart failure with preserved ejection fraction, where beta-blockade lacks a comparable mortality benefit — and much prescribing does not observe the distinction.
3. Beta-blockers for AF rate control rest on weaker ground than their ubiquity implies. The AFFIRM-era evidence concerns rate versus rhythm strategies rather than which rate-control agent is best, and there is a recognised signal that beta-blockade may be less beneficial in patients who have AF and heart failure than in those in sinus rhythm.
4. The 'continue rather than stop in decompensation' position is based largely on observational data, not randomised trials, and the honest framing is that abrupt withdrawal has demonstrable harms while continuation in a hypoperfused patient has obvious risks. Dose reduction is a pragmatic middle path rather than a proven strategy.
5. Cardioselectivity is real but partial, and the pendulum on beta-blockade in obstructive airways disease has swung considerably. Severe asthma remains a genuine contraindication; mild COPD with a strong cardiac indication generally does not.

References

1. 1
   Bisoprolol Fumarate film-coated tablets — Summary of Product Characteristics. electronic Medicines Compendium. Sections 4.1–4.4. Verified 20 Aug 2026.
2. 2
   Bisoprolol fumarate — dosing and safety monograph. BNF, NICE. bnf.nice.org.uk
3. 3
   CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353(9146):9–13.
4. 4
   NICE NG106. Chronic heart failure in adults: diagnosis and management. National Institute for Health and Care Excellence.
5. 5
   NICE NG196. Atrial fibrillation: diagnosis and management. National Institute for Health and Care Excellence.
6. 6
   Resuscitation Council UK. Adult tachyarrhythmia algorithm, 2025. resus.org.uk — mirrored at lifesupport.resusdoc.uk. Beta-blockade remains a rate-control option at EF below 40%, where calcium channel blockers do not.
7. 7
   TOXBASE — beta-blocker poisoning. National Poisons Information Service. toxbase.org (NHS login required.)